NeOnc Technologies Holdings, Inc. Common Stock Cash Flow Conversion Efficiency
NeOnc Technologies Holdings, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, NeOnc Technologies Holdings, Inc. Common Stock (NTHI) has a cash flow conversion efficiency ratio of 0.257x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.77 Million) by net assets ($-18.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NeOnc Technologies Holdings, Inc. Common Stock (2021–2025)
Cash flow conversion efficiency of NeOnc Technologies Holdings, Inc. Common Stock from 2021 to 2025. This chart illustrates how NeOnc Technologies Holdings, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NTHI live share price for real-time trading data and today's change.
NeOnc Technologies Holdings, Inc. Common Stock Cash Flow Conversion Ratio Explained
NeOnc Technologies Holdings, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NeOnc Technologies Holdings, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NeOnc Technologies Holdings, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see NTHI market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kingfisher PLC
LSE:KGF
|
0.120x |
|
Igis Residence Reit Co Ltd
KO:350520
|
N/A |
|
LG HelloVision Corp
KO:037560
|
0.009x |
|
Abeo SAS
PA:ABEO
|
-0.050x |
|
Deutsch Motors Inc
KQ:067990
|
0.066x |
|
Centrale d'Achat Française pour l'Outre-Mer Société Anonyme
PA:CAFO
|
0.140x |
|
Ahn-Gook Pharmaceutical Co. Ltd
KQ:001540
|
0.086x |
|
Income Opportunity Realty Investors
NYSE MKT:IOR
|
-0.001x |
Annual Cash Flow Conversion Efficiency for NeOnc Technologies Holdings, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of NeOnc Technologies Holdings, Inc. Common Stock from 2021 to 2025. Review NeOnc Technologies Holdings, Inc. Common free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-17.51 Million | $-20.36 Million | 1.163x | +51.95% |
| 2024-12-31 | $-5.50 Million | $-4.21 Million | 0.765x | +469.55% |
| 2023-12-31 | $-13.99 Million | $-1.88 Million | 0.134x | -75.99% |
| 2022-12-31 | $-1.58 Million | $-881.74K | 0.560x | +269.14% |
| 2021-12-31 | $-2.62 Million | $-396.69K | 0.152x | -- |
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical… Read more